Fractures due to Aromatase Inhibitor Therapy for Breast Cancer: A Real-World Analysis of FAERS Data in the Past 15 Years
Author:
Publisher
S. Karger AG
Subject
Cancer Research,Oncology,Hematology
Reference20 articles.
1. Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al.; SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):127–38.
2. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 2005 May;26(3):331–45.
3. Wu B, Shah SN, Lu P, Bollinger LE, Blaeser A, Sparks S, et al. Long-Term Treatment of Tamoxifen and Raloxifene Alleviates Dystrophic Phenotype and Enhances Muscle Functions of FKRP Dystroglycanopathy. Am J Pathol. 2018 Apr;188(4):1069–80.
4. Berruti A, Tucci M, Mosca A, Vana F, Ardine M, Dogliotti L, et al. Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients. J Clin Oncol. 2007 Apr;25(11):1455–6.
5. Mccaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, et al. A randomised study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover. Cancer Res. 2009;69:1145.
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-08-20
2. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system;Frontiers in Pharmacology;2024-07-10
3. Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database;Expert Opinion on Drug Safety;2024-07-10
4. A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib;Scientific Reports;2024-05-18
5. Vitreoretinal Traction Syndrome, Nitrituria and Human Epidermal Growth Factor Receptor Negative Might Occur in the Aromatase-Inhibitor Anastrozole Treatment;International Journal of Clinical Practice;2024-05-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3